The Herald
Sifelani Tsiko Agric, Environment & Innovations EditorThe mere mention of genetically modified foods (GMOs) has stirred emotions and popular consternation around the issue of altered foods, with concerns over health and its effects on the environment. So much has been said about GMOs, with various people on opposing sides making various claims substantiated and unsubstantiated.
The result has been fear, confusion and meaningless propaganda.
Fear of new technology has generated mixed feelings marked by initial scepticism followed with embrace and adoption after noting the benefits.
Despite a blanket ban on GMOs in Zimbabwe, scientists have been doing research on GMO crops for years benefiting other countries which they have been sharing their findings with.
Darlington Mutetwa, a Quton plant breeder, has spearheaded efforts to promote the growing genetically modified cotton in Nigeria, Malawi and other African countries.
Renowned University of Zimbabwe biochemist Prof Idah Sithole-Niang has also been at the forefront of promoting the growing of GM crops from maize, cowpeas, Bt cotton and others globally without much recognition back home.
The same goes for a number of top Zimbabwean academics who are working in various top global companies using biotechnology to promote the development of various agricultural and medical products.
All this has been going on without Zimbabwe benefiting from its talent and the emerging technology, simply because the country is not willing to adopt the new technologies.
Zimbabwe, for long has been a hostile place for researchers testing genetically modified crops.
Through a combination of regulations, bureaucracy, mistrust and fear, the Government has barred the commercial planting of a transgenic crops.
Anti-GM activists have also added to the woes, but under the new dispensation, things are changing.
Higher and Tertiary Education, Science and Technology Development Minister Professor Amon Murwira has been bold and aggressive in terms of re-orienting the education system under five terms of reference which includes teaching, research, community engagement, innovation and industrialisation.
He has come out strongly and supported science and technology development to promote the new products, platforms and solutions that embed best practice to support the countrys industrial and technological development.
The space is opening up for scientists who are keen on GM crop development.
And, recently, the National Biotechnology Authority of Zimbabwe organised the biosafety sensitisation and consultative workshop to demystify biotechnology and GMOs for parliamentarians and other stakeholders.
The hosting of the event was supported by the African Union Development Agency-New Partnership for Africas Development/African Biosafety Network of Expertise (AUDA-NEPAD/ABNE), an African Union (AU) organisation responsible for supporting the building of functional biosafety regulatory systems in African Union member states.
All this demonstrates the opening up of space for scientists and the international research community to play their part in creating an enabling environment for Zimbabwe to adopt new technologies that can enhance agricultural productivity.
Years of unnecessary anti-GMO debate in Zimbabwe has missed the mark.
We should not just single out GMOs for criticism, but also look at the impact of the vast amount of chemicals nitrogen fertilisers and synthetic pesticides used in our conventional agricultural system.
These also have serious implications on health and the environment. Our scientists are quite clear about GM technology that it is not a silver bullet solution, but one crop strategy we can employ to enhance our crop yields and reduce our costs.
Our own biochemists, Prof Christopher Chetsanga and Prof Sithole-Niang, have spoken out eloquently on the subject and outlining the potential benefits of GM crops.
They have said that Zimbabwe should go step by step and start with GM cotton as plunging into GM food crops totally may be too risky and controversial.
They are saying Zimbabwe should at least move to do trials for Bt cotton to boost cotton production.
Government wants to prioritise digitisation and technology and innovation in order to achieve meaningful development in the country and the region.
To meet the Fourth Industrial Revolution in Zimbabwe and the SADC region, our country has pledged to promote emerging technologies in a number of fields such as robotics, artificial intelligence, nanotechnology, quantum computing, big data, biotechnology, fifth generation wireless technology and 3D printing.
Prof Sithole-Niang says if the growing of genetically modified cotton is allowed in Zimbabwe it could be a boon for the State.
She says if we adopt GM cotton we can save up to US$90 million a year in terms of reduced production cost.
The country, she argues, could also get $40 million in incremental revenue every year through improved crop yields and reduced cost of production.
Zimbabwe was the first country in Africa to conduct confined field trials for GM cotton and maize around 2000 before the country put a blanket ban on GM crop trials and food by 2005.
And as a result, biotechnology experts say the country has lost out on the potential benefits of new agricultural technologies that can significantly boost yields, incomes and improve livelihoods.
Zimbabwe has not adopted GMO crop technologies, but established the National Biotechnology Authority in 2006 to regulate research, transport, import, manufacture, safe handling and use of organisms and products of modern biotechnology.
In its Second Science, Technology and Innovation Policy released in March 2012, the country identified biotechnology as one of the most promising tools that can help increase food productivity, enhance the health and wellness of society and boost manufacturing output.
While Zimbabwe is delaying the adoption of GM crops, other countries such as South Africa have been growing GM maize, soyabean and cotton for nearly two decades with latest statistics indicating plant hectarage of some 2,7 million hectares.
There has been a massive spread of GMO products in Zimbabwe and across the entire SADC region which include maize, cotton and soyabean, livestock feed, tobacco, bananas, potatoes, poultry products and vegetables.
South Africa has embraced GMOs and as the regions strongest economy it has been impossible to stop the penetration of GMO foods.
Worse still, with drought ravaging Zimbabwe and most other SADC countries, food aid has come from the US and China, which are now among the biggest producers of GM maize.
No matter what we do, Zimbabwe cannot stop the emergence and movement of new technologies. We only have to adopt the new technologies and take the necessary biosafety measures to minimise the potential risks.
We are legging behind.
In 2018, Sudan cultivated 243 000 ha of Bt cotton, eSwatini 250ha, while in 2019 Ethiopia planted Bt cotton on more than 500 000ha, according to the International Service for the Acquisition of Agri-biotech Applications (ISAAA) 2018 report.
Nigeria, Malawi and Kenya have given cultivation approvals for Bt cotton. More than 70 percent of cotton traded global is GM cotton.
India and China are among some of the biggest producers of Bt cotton where Zimbabwe imports some of its clothing materials from.
As a country we are consuming GMO products and it only makes sense to get on the train and start growing GM cotton for a start.
We have the technical expertise and what we need are resources and the political will.
Debate on GMOs is quite controversial and anyone who touches GMOs gets burned. People are so worked up on both sides that no matter what you say, someone will criticise you. We should raise concerns using facts. We should utilise scientists to drive our own biotechnology agenda.
We should not lose ourselves to fear and confusion.
Biotechnology is big business and as a country we should harness it for our benefit. Cuba, South Africa, China, US, Sudan, Egypt and many other countries are using biotechnology for their benefit.
Zimbabwe should allow our scientists to conduct confined field trials for genetically modified crops as part of efforts to find innovative solutions to some of the pressing problems facing the countrys agricultural sector.
We have the capacity to do it. Our universities are training biotechnology students who are being taken outside and benefiting other countries.
Why should we waste our resources and fail to tap on the benefits of this technology when we have the capacity to harness it?
See the article here:
Why Zim must harness benefits of biotechnology - The Herald
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022